Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., Brinton, E. A., Eckel, R. H., Elam, M. B., Felicio, J. S., Ginsberg, H. N., Goudev, A., Ishibashi, S., Joseph, J., Kodama, T., … Ridker, P. M. (2022). Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk. New England Journal of Medicine, 387(21), 1923–1934. https://doi.org/10.1056/nejmoa2210645

Ginsberg, H. N., Hounslow, N. J., Senko, Y., Suganami, H., Bogdanski, P., Ceska, R., Kalina, A., Libis, R. A., Supryadkina, T. V., & Hovingh, G. K. (2022). Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy. Diabetes Care, 45(4), 898–908. https://doi.org/10.2337/dc21-1288